Disease progression and recurrence in pancreatic and colorectal cancer Cancer
Conditions
Interventions
Eligible patients will be recruited in the study and will undergo further genomic testing of the acquired biopsies for diagnostic purposes to determine the genetic profile of the primary tumours and r
Sponsors
NHS Tayside
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. All patients with a new diagnosis of pancreatic or colorectal cancer between ages 18-80 years 2. A cohort of healthy individuals (no previous cancer diagnosis) will be the control group and will need to provide a sample of peripheral blood samples to prove the lack of mutant genetic material in their bloodstream
Exclusion criteria
Exclusion criteria: 1. For participants with a pancreatic or colorectal cancer diagnosis: past medical history of a different primary malignancy 2. For healthy participants: previous diagnosis of cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA levels for cancer-specific mutations measured with next-generation sequencing (NGS) at baseline and every 2 months between treatment modalities, until proof of disease recurrence or patient death/loss to follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement in days of the lead changes in ctDNA levels compared to evidence of disease recurrence on traditional biomarkers (CA19-9, CEA) and on imaging (CT, MRI) | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactGeorgios Gemenetzis
Outcome results
None listed